A Retrospective Analysis of the Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine.
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Capecitabine (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Pharmacogenomic
- 08 May 2017 Biomarkers information updated
- 27 Aug 2013 Planned end date changed from 1 May 2014 to 1 May 2015 as reported by ClinicalTrials.gov..
- 17 May 2012 Planned end date changed from 1 May 2011 to 1 May 2014 as reported by ClinicalTrials.gov.